Downregulation of surface PD-L1 in tumor cells by metformin and etoposide enhances the efficacy of anti-CTLA-4 and anti-TIM therapies.26,27 PD-L1 glycosylation is also regulated by EGFR signaling. Here, CD274 is linked to neoplasm.